The Gastrointestinal Oncology Program Is a comprehensive program in gastrointestinal cancer research encompassing basic research, clinical and translational research. The program consists of 39 members from 9 different departments and two schools within the University of Michigan, receiving $9 million in annual direct support, Including $4.4 in NCI funding. The GI grant portfolio includes a $2.1 M SPORE grant to study colorectal and pancreatic cancer, two PO1 grants, U01 and U19 grants. The program is focused on the development of fundamental basic research into the causes and prevention of human gastrointestinal cancers and translational studies applying these research findings to improve the early and accurate diagnosis, evaluation, and therapeutic approaches to gastrointestinal cancer as well as Issues related to health quality outcomes, The basic research alms of the Gastrointestinal Oncology Program focus on mechanisms of cell growth and differentiation, stem cells and cell metastasis. The clinical research focuses on neoadjuvant therapies and biomarkers. The outcome research focuses on health care quality Issues. Nine new program members recruited over this grant period include Drs Marwan Fakih, Weiping Zou, Grace Chen, Chandan Kumar, Marina Pasca Di Magliano, Patrick Hu, Gazala Khan, Theodore Welling, and John Carethers. This program, which was rated as
The GI Oncology Program is dedicated to providing state-of-the art clinical care of patients with neoplasms of the GI tract in a multidisciplinary setting. This allows optimal tumor treatment based on input from multiple disciplines, Including surgery, medical and radiation oncology, gastroenterology, and interventional radiology. The GI oncology program also has a major focus on basic and translational research to develop a more effective approach to cancer prevention and the development of novel, more effective therapeutics.
Showing the most recent 10 out of 1493 publications
